Comparison

Mazdutide vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Mazdutide

Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Mazdutide	VK2735
CN	Prescription	—
Germany	Research only	Unapproved
United States	Research only	Unapproved

Full entries

Frequently asked questions

What is the difference between Mazdutide and VK2735?: Mazdutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Mazdutide or VK2735?: The highest available evidence level is "Human RCT" for Mazdutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Mazdutide and VK2735 in Germany and the United States?: Germany: Mazdutide — Research only, VK2735 — Unapproved. United States: Mazdutide — Research only, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Mazdutide

VK2735

Prescription

—

Germany

Research only

Unapproved

United States

Research only

Unapproved

Frequently asked questions

What is the difference between Mazdutide and VK2735?

Mazdutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Mazdutide or VK2735?

The highest available evidence level is "Human RCT" for Mazdutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Mazdutide and VK2735 in Germany and the United States?

Germany: Mazdutide — Research only, VK2735 — Unapproved. United States: Mazdutide — Research only, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.